Business
Theralase(R) Grants Stock Options
TORONTO, ON / ACCESSWIRE / September 21, 2023 / Theralase® Technologies Inc. (" Theralase&#...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase(R) Grants Stock OptionsTORONTO, ON / ACCESSWIRE / September 21, 2023 / Theralase® Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV:TLT) (OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDCs\"), their associated drug formulations and the light systems that activate them, intended to safely and effectively destroy various cancers, announces the grant of stock options.The Company has granted an aggregate of 360,000 stock options to certain directors and employees pursuant to the Company's stock option plan. The options granted, are exercisable at a price of $CAN 0.25 per share that vest over a three-year period and expire five years from the date of the grant. The stock option plan was last approved by the shareholders of the Company at the Annual General and Special Meeting of Shareholders held on June 29, 2023.About Theralase® Technologies Inc.:Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.Additional information is available at www.theralase.com and www.sedar.comNeither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Forward Looking StatementsThis news release contains \"forward-looking statements\" within the meaning of applicable Canadian securities laws. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Forward looking statements may be identified by the use of the words \"may, \"should\", \"will\", \"anticipates\", \"believes\", \"plans\", \"expects\", \"estimate\", \"potential for\" and similar expressions including statements related to the current expectations of Company's management for future research, development and commercialization of the Company's Photo Dynamic Compounds and their drug formulations, including preclinical resea...